After incubation of ovarian cancer cells with scFv-Farletuzumab-SNAP-IR700, high-FOLR1-expressing IGROV1 cells exhibited strong binding and moderate-FOLR1-expressing OVCAR3 cells showed moderate binding, whereas no fluorescence signal was detected in low-FOLR1-expressing cell lines (Figure 2). This evidence concerns the gene FOLR1 and ovarian carcinoma.